Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
2014-001929-32Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Aug 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in diffuse intrinsic pontine glioma (DIPG) and brainstem glioma comparing Erlotinib + radiotherapy, Everolimus + radiotherapy and Dasatinib + radiotherapy (3 arms). Primary endpoint: Overall survival (2-year OS primary). Started Aug 2014; status: active.
02
Drugs
erlotinibeverolimusdasatinib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)brainstem glioma
Beyond the preview
Go deeper on 2014-001929-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001929-32.